Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial
An experimental Eli Lilly drug led to greater improvement on measures of type 2 diabetes compared to the approved Novo drug Ozempic, Phase 3 results that further build the case…
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 28 14:12 ETSource: MedCity News
From the source
Read at medcitynews.comEli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial
An experimental Eli Lilly drug led to greater improvement on measures of type 2 diabetes compared to the approved Novo drug Ozempic, Phase 3 results that further build the case for the closely watched peptide that’s engineered to hit three metabolic targets in the gut.
